Your browser doesn't support javascript.
loading
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das, Ishani; Wilhelm, Margareta; Höiom, Veronica; Franco Marquez, Rodolfo; Costa Svedman, Fernanda; Hansson, Johan; Tuominen, Rainer; Egyhàzi Brage, Suzanne.
Afiliação
  • Das I; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Wilhelm M; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Höiom V; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Franco Marquez R; Department of Pathology and Cytopathology, Hospitatal Univeristario, UANL, Nuevo Leon, Mexico.
  • Costa Svedman F; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Hansson J; Karolinska University Hospital, Stockholm, Sweden.
  • Tuominen R; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Egyhàzi Brage S; Karolinska University Hospital, Stockholm, Sweden.
Cell Death Dis ; 10(9): 663, 2019 09 10.
Article em En | MEDLINE | ID: mdl-31506424

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article